1.

B

- (Twice Amended) A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual a therapeutically effective amount of human acid α -glucosidase periodically at an administration interval, wherein the human acid α -glucosidase was produced in chinese hamster ovary cell cultures.
- 11. (Amended) The method of Claim 1, wherein the administration interval is monthly.

Br

- 12. (Amended) The method of Claim 1, wherein the administration interval is bimonthly.
- 13. (Amended) The method of Claim 1, wherein the administration interval is weekly.
- 14. (Amended) The method of Claim 1, wherein the administration interval is twice weekly.
- 15. (Amended) The method of Claim 1, wherein the administration interval is daily.

83

- 21. (Twice Amended) A method of treating cardiomyopathy associated with glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual a therapeutically effective amount of human acid α-glucosidase periodically at an administration interval, wherein the human acid α-glucosidase was produced in chinese hamster ovary cell culture
- 22. (Twice Amended) A pharmaceutical composition comprising human acid α-glucosidase, wherein the human acid α-glucosidase was produced in chinese hamster ovary cell culture, in a container, the container having a label containing instructions for administration of the composition for treatment of glycogen storage disease type II.

Please add Claim 23:

BY

23. (New) The method of Claim 1, wherein the administration interval is varied over time.